Clinical Trials
19
Active:2
Completed:4
Trial Phases
4 Phases
Phase 1:5
Phase 2:7
Phase 3:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (36.8%)Phase 1
5 (26.3%)Phase 3
5 (26.3%)Not Applicable
2 (10.5%)Phase I Trial of GR1803 Injection in Patients With RRMM
Not Applicable
Completed
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Drug: GR1803 injection
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT07102706
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: GR1803 injectionDrug: Anti-CD38 Monoclonal Antibody
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07090954
- Locations
- 🇨🇳
Shanghai Fourth People's Hospital Affiliated with Tongji University, Shanghai, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
GR1803 Injection in Patients With RRMM
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06952075
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
Phase 2
Recruiting
- Conditions
- Asthma
- Interventions
- Other: PlaceboDrug: GR1802 injection
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06642961
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 582
- Registration Number
- NCT06635798
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found